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Purpose: To examine early cellular changes, including astrocyte reactivity and microglial activation, in the central nervous
system (CNS) after unilateral optic nerve transection (ONT) or ocular hypertension (OHT) in monkeys.
Methods: Unilateral ONT or OHT was achieved in monkeys for periods ranging from two weeks to two months in
duration. After intracardial perfusion, sections of the lateral geniculate nucleus (LGN) and visual cortex (V1) were
examined by immunohistochemistry for glial fibrillary acidic protein (GFAP) and CD11b, a subunit of the complement
3 receptor and marker of macrophage and microglia cells (MAC-1). Alternate serial sections were evaluated by cytochrome
oxidase (CO) histochemistry to assess metabolic activity.
Results: Both ONT and OHT caused a reduction in metabolic activity in the treated eye layers of the LGN and V1. GFAP
and MAC-1 immunoreactivities were elevated in spatial register with the treated eye layers of the LGN and V1 in ONT
animals. In the OHT animals, GFAP, but not MAC-1, immunoreactivity was elevated in spatial register with the treated
eye layers of LGN and V1. Thus, during the first weeks after OHT or ONT, loss of metabolic activity was accompanied
by astrocyte and microglial activation in the ONT group and astrocyte activation in the OHT animals.
Conclusions: These results suggest that unilateral OHT or ONT triggers separate signaling pathways that promote
differential activation of CNS glial populations. Astrocyte reactivity was present in all brains studied and demonstrates
the loss of metabolic activity is accompanied by increased GFAP immunoreactivity. Microglial activation was only
observed in ONT brains. The lack of microglial activation as late as two months following OHT may represent a time
window for early treatment to prevent long-term neuronal loss in the CNS after OHT.
Glaucoma is a condition which causes a loss of retinal
ganglion cell activity. This loss has been shown to cause
neurochemical  changes  in  the  lateral  geniculate  nucleus
(LGN)  and  visual  cortex  of  adult  primates.  Studies  have
revealed  that  the  activity  of  the  mitochondrial  enzyme,
cytochrome oxidase (CO) is reduced after monocular visual
deprivation by lid suture (MD), tetrodotoxin (TTX) injection,
enucleation, and optic nerve transection (ONT) in adult cats
and  primates  [1-8].  The  development  of  an  experimental
ocular hypertension (OHT) model using primates, in which
intraocular pressure (IOP) is elevated, allows us to study the
effects  of  a  visual  loss  that  more  closely  mimics  the
neurodegenerative  processes  associated  with  human
glaucoma [9,10]. Using such primate models, it was shown
that  elevation  of  IOP  causes  selective  damage  of  retinal
ganglion  cells  [11-14],  and  alterations  in  the  neuronal
structure  and  neuromodulatory  chemicals  in  the  LGN
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[15-20]  and  in  V1  of  the  central  nervous  system  (CNS)
[21-23]. In glaucoma patients, elevated IOP may cause axonal
dysfunction with or without retinal ganglion cell loss, leading
to subsequent visual field defects [24,25] and central changes
in the LGN and V1 [26-29].
Several studies reported that elevated IOP lasting for one
year or more results in neurodegenerative events including
neuronal  atrophy,  shrinkage  of  dendritic  arbors,  and  a
reduction in both the number and diameter of neurons in the
retina and brain [12-14,18-20]. These studies highlight the
later stages of neurodegeneration in the CNS after vision loss
by  long-term  elevated  IOP.  As  the  loss  of  neurons  is
irreversible in the adult CNS, there is an important need to
focus on the early events that take place in the CNS after
elevated IOP before cell loss, to develop strategies to prevent
neuronal atrophy and loss both in the eye and the brain.
Among  the  earliest  cellular  events  after  sensory
deafferentation are the loss of CO activity and the activation
of glial cells, which have been shown to occur within hours
after  action  potential  blockage  by  TTX  injection  or
deafferentation [3,30-32]. In the CNS, glial cells outnumber
neurons by a factor of ten and serve a supportive role by
surrounding neuronal cell bodies, axons, and dendrites. Their
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2217function  ranges  from  providing  structural  support  in  the
normal healthy CNS, to removing debris after cell death and
injury. A major class of glial cells, the astrocyte, functions in
daily  maintenance  of  the  extracellular  milieu  and  also
regulates  the  cerebral  vasculature  and  neuronal  activity
[33-36]. In response to traumatic injury, astrocytes multiply,
increase the production of intermediate filaments, and later
form dense gliotic scars to contain damaged tissues [37-41].
Another major class of glial cell, the microglia, monitors ion
levels and neurotransmitter changes in the extracellular matrix
[42-47].  In  their  activated  state,  microglia  proliferate  and
migrate  to  sites  of  injury  or  disease,  where  they  remove
cellular  debris  [46,48].  Activated  microglia  also  produce
inflammatory  cytokines  that  promote  microglial  and
macrophage  migration,  and  may  ultimately  result  in
secondary neuronal damage due to the generation of reactive
oxygen species via respiratory burst mechanisms and thus,
may  themselves  promote  inflammation  and
neurodegeneration.
Little  is  known  of  the  glial  response  in  the  CNS  of
primates  after  elevated  IOP;  however,  earlier  studies  in
rodents revealed that microglial cells become activated and
lead to neuronal cell death in the LGN [49]. The objective of
this study was to identify the early changes in neuronal activity
and  glial  activation  in  the  LGN  and  V1  after  short-term
unilateral elevated IOP (two weeks to two months) in primates
with OHT. For comparison, we also studied the glial response
to ONT, a form of deafferentation that is known to cause
immediate  and  irreversible,  transsynaptic  (anterograde)
degeneration in the CNS. Understanding the neurochemical
changes in the CNS after short-term elevated IOP may lead to
developing  strategies  for  early  detection  or  protection  of
surviving  neurons,  both  in  the  retina  and  brain,  from
neurodegeneration associated with glaucoma.
METHODS
This  study  used  eight  rhesus  (Macaca  mulatta)  and  four
cynomolgus (Macaca fascicularis) monkeys that were ages 3
to 24 years. All 12 male and female monkeys were treated at
the University of Wisconsin, Madison, WI. Animals were
acquired  from  Covance  Labs,  Madison,  WI,  Wisconsin
National Primate Research Center, Madison, WI or Bioqual,
Rockville, MD. All monkeys were housed in standard 12 h
cycle lighting with water ad libitum and food provided twice
a day. The enrichment program included social housing, toys/
objects to manipulate, cage furniture, foraging devices, fruit,
and  other  nutritive  snacks,  radio  and  TV/movies.  All
experiments  were  done  in  accordance  with  the  ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research as well as with National Institutes of Health and
University of Wisconsin guidelines.
Animal  surgical  procedures:  Two  rhesus  and  two
cynomolgus  monkeys  underwent  laser  ablation  of  the
trabecular meshwork [10,50] in one eye, which resulted in
ipsilateral elevated IOP for periods of two to eight weeks
(Table  1).  A  standard  clinical  argon  laser  and  slit  lamp
delivery system was used to produce a series of 75 to 250 focal
lesions  to  the  trabecular  meshwork.  The  laser  was  set  to
deliver a 50 μm spot diameter at 1–1.5 W with a 0.5 s duration.
Two additional animals had spontaneous unilateral elevation
of IOP. These animals had developed unilateral secondary
glaucoma  due  to  persistent  inflammation  following
intracameral injection of different experimental drugs. IOP
was monitored every three to ten days under intramuscular
(IM) injection of 10 mg/kg ketamine anesthesia (3–5 mg/kg
supplement  as  needed)  using  a  minified  Goldmann
applanation  tonometer  [51]  (Haag-Streit,  Koniz,
Switzerland). These measurements were occasionally backed
up by measurements with a handheld applanation tonometer
(Tono-pen  XL;  Mentor  O  &  O,  Norwell,  MA).  Tonopen
measurements were converted to actual mmHg based on a
standard calibration curve [52]. IOP was measured with the
monkey  lying  prone  in  a  head  holder.  If  IOP  was  not
consistently above 30–35 mmHg, additional laser treatments
were  performed  until  stable  ocular  hypertension  was
achieved. IOP was checked every three to ten days thereafter
to assure stability. Additional laser treatment or IOP lowering
therapy was applied as needed to maintain IOP at the desired
level. If the IOP was higher than the protocol target range or
if there was any sign of discomfort due to elevated IOP, the
monkeys were treated topically once or twice daily with a
single drop of one or more of the following until the desired
IOP  was  achieved:  0.5%  timolol  maleate  in  gel-forming
vehicle (Timoptic-XE; Merck & Co., Whitehouse Station,
NJ), 0.2% brimonidine tartrate (Alphagan; Allergan, Irvine,
CA), 2% dorzolamide hydrochloride (Trusopt; Merck & Co.),
and 2 μg prostaglandin F2 alpha-isopropyl ester (donated by
Pharmacia Corp, Peapack, NJ). If necessary, 5 mg/kg IM
acetazolamide  sodium  (Ben  Venue  Laboratories,  Bedford,
OH) was given once or twice daily. The opposite eye served
as a normal control eye.
Quantification of vision loss experienced by animals with
unilateral  ocular  hypertension  was  calculated  using  an
“integral”  value,  defined  as  the  number  of  days  of  IOP
measurements >30 mmHg multiplied by the mean IOP value
for that period of time [53]. Vision loss by ONT was quantified
by the total number of days after ONT surgery and before
euthanasia. A summary of these values is shown in Table 1.
Six additional rhesus monkeys underwent unilateral optic
nerve transection [54] (Table 1). Animals were given an initial
IM injection of 10–15 mg/kg ketamine, which was followed
by  intubation,  then  general  anesthesia  under  1%–3%
isoflurane gas.  After  surgery, monkeys were treated with
systemic benzathine and 30,000 U/kg procaine penicillin for
five days and 1mg/kg IM methylprednisolone acetate for three
weeks,  tapering  to  0.1  mg/kg  for  1  more  week.  As  an
analgesia, 0.1 mg/kg IM injection of buprenorphine was given
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 for three days. Two animals were euthanized with 1 ml/4.5 kg
intravenous  Euthasol  (each  milliliter  contains  390  mg  of
pentobarbital and 50 mg of phenytoin) at two weeks following
the surgery, and the remaining four animals were euthanized
at four weeks following ONT surgery.
Tissue processing: All twelve animals were euthanized
and  perfused  intracardially  with  750  ml  phosphate  buffer
saline (PBS; 9 g/l NaCl, 3.96 g/l NaH2PO4-H2O, and 22.68 g/
l  HNa2O4P-7H2O),  followed  by  one  liter  of  4%
paraformaldehyde and again with 200–300 ml PBS following
25 mg/kg IV pentobarbital anesthesia. The brain was removed
and placed in a solution of 10% sucrose in phosphate buffer
and  shipped  on  ice  packs  by  overnight  courier  to  the
University of British Columbia. Upon arrival, area V1 and
LGN sections were dissected from the rest of the brain. Area
V1  was  blocked  such  that  it  could  be  gently  flattened
tangentially between two glass slides before being frozen on
dry ice and stored at −80 °C. The LGN was blocked in the
coronal plane, frozen on dry ice and stored at −80 °C as
previously described [23].
CO histochemistry and immunohistochemistry: Tissue
blocks  were  cut  tangentially  at  50  μm  on  a  freezing
microtome. Alternate 50 μm sections were stained for CO
activity  using  previously-published  protocols  [23,55].
Briefly, 20 mg of diaminobenzidine (DAB; Sigma-Aldrich,
St. Louis, MO) was dissolved in 50 ml of distilled water. Once
dissolved, 50 ml (0.1 M, pH 7.2) phosphate buffer (PB), 2 g
sucrose, 30 mg cytochrome C (Sigma-Aldrich) derived from
horse heart and 20 mg of catalase (Sigma-Aldrich) derived
from bovine liver were added to the DAB solution. Then, 5 ml
of 1% nickel ammonium sulfate was added dropwise followed
by approximately 3 ml of 1% cobalt chloride until the solution
appeared slightly opaque. Tissue sections were placed into 12-
well  plates  filled  with  1.5  ml  of  the  cytochrome  oxidase
solution  and  incubated  at  37  °C  for  30–45  min.  Upon
completion of the reaction, sections were washed three times
for 5 min each in PB. Then the sections were mounted onto
glass slides and air dried overnight. Mounted sections were
then dehydrated in a series of graded alcohols and cleared in
xylene.  Mounting  medium,  Permount  (Fisher  Scientific,
Waltham  MA)  was  applied  onto  sections  and  then
coverslipped.
Monoclonal antibodies against human CD11b (MAC-1;
Cederlane Labs, Burlington, VA) and glial fibrillary acidic
protein  (GFAP;  Chemicon,  Temecula,  CA)  were  used  to
identify  activated  microglial  and  astrocytes,  respectively.
Free-floating sections were incubated in 3% normal horse
serum (NHS) for 1 h to block nonspecific binding, and then
washed three times for 5 min each in PB before incubating in
primary antibodies. Primary antibodies against MAC-1 and
GFAP were used at a 1:300 dilution in 3% NHS in 0.3% Triton
X-100 (TX-100) made in PB. After rinsing, sections were
incubated at 4 °C in primary antibody for 36 to 48 h with
agitation. They were then rinsed three times for 5 min each in
PB  before  incubating  in  0.1%  secondary  antibody
(biotinylated anti-mouse made in horse) in 3% NHS and 0.3%
TX-100 in PB for 2 h at room temperature. Next, sections were
placed  in  a  solution  of  avidin  biotin  complex  (Vector
Laboratories, Burlingame, CA) for 1 h. Visualization of the
antibody binding was undertaken using a glucose oxidase
driven DAB as described previously [23,55]. Sections were
mounted  on  gelatin-coated  slides,  air-dried,  dehydrated,
cleared in xylene and coverslipped with Permount (Fisher
Scientific). Negative control sections were processed after the
primary antibody was replaced with a solution containing 3%
NHS and 0.3% TX-100.
Data collection and analysis: Images of processed LGN
and V1 sections were captured using standard digital camera
settings and 1×, 20×, 40×, and 100× objective lenses attached
to  an  upright,  bright-field  compound  microscope  (Nikon,
Tokyo Japan). Serial sections were aligned using the pattern
of blood vessels as fiduciary landmarks. High power images
of GFAP and MAC-1 immunoreactivity (Figure 1D-I, Figure
2D-I, Figure 3D-I, and Figure 4D-I) were taken using a 100×
oil  objective  lens.  A  semiquantitative  analysis  of  the
immunoreactivity was assessed using three microscope fields
in each of three tissue sections for a total of nine microscope
fields. The intensity of immunoreactivity in the treated eye
layers was scored in a semiquantitative manner. Background
immunoreactivity was represented with a minus sign (−). One
plus (+) represented moderate immunoreactivity, while two
pluses  (++)  represented  significant  immunoreactivity  (see
Table 1). The diameters of the immunoreactive cell profiles
were measured using a 40× objective and 10× eyepieces and
expressed as mean±SD (Figure 5). A paired t-test (Minitab
Statistical Software, State College, PA) was used to compare
the measurements of cell profile diameters for GFAP and
MAC  −1  populations  and  a  two  sample  t-test  (Minitab
Statistical  Software)  was  used  to  compare  the  GFAP
populations between ONT and OHT tissues.
RESULTS
Animals  with  optic  nerve  transection:  CO  histochemistry
revealed light CO staining in layers 1, 4, and 6 of the LGN, a
pattern that confirmed that the transected optic nerve (right)
was contralateral to the processed hemisphere (left) in five of
the six brains (Figure 1A,D,E). CO staining in layers 2, 3, and
5, the ipsilateral layers of the LGN, demonstrated darker CO
staining and represented normal levels of CO activity in both
the 14 day and the 28 day post ONT brains. In one animal
(AP75), the hemisphere ipsilateral to the transected nerve was
processed; CO histochemistry revealed light CO staining in
the ipsilateral layers of the LGN (layers 2, 3, and 5). The
relative density of the CO staining in the treated magnocellular
and parvocellular layers of the LGN was equally reduced after
ONT. CO histochemistry of tangential sections through V1
revealed  a  series  of  lightly  and  darkly  staining  ocular
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2220dominance bands in layer 4C (Figure 2A,D,E) and blobs in
layer 2/3 (not shown), reflecting the transsynaptic loss of
geniculocortical  afferent  activity  associated  with  the
transected nerve. This pattern of CO staining in the LGN and
V1  is  consistent  with  earlier  studies  [1,4,5,7,8]  in  which
animals were subjected to ONT or MD by lid suture.
Astrocytic  reactivity  was  assessed  with  GFAP
immunoreactivity.  All  ONT  brains  processed  for  GFAP
immunoreactivity demonstrated a pattern of robust labeling in
the treated eye layers of the LGN (n=4) and the treated ocular
dominance bands of area V1 (n=5; Figure 1B,F,G; Figure
2B,F,G, and Figure 6B,C). GFAP immunoreactivity revealed
cytoplasmic labeling of astrocyte somata and their highly
ramified  processes  (Figure  1F  and  Figure  2F).  The  mean
diameter  of  the  GFAP  immunoreactive  cell  bodies  in  the
parvocellular layers of the LGN was 14.2 µm (±0.4 SD). The
mean diameter of the GFAP immunoreactive profiles in V1
was 11.8 µm (±0.9 SD). GFAP immunoreactivity also resulted
in  strong  labeling  of  highly  ramified  processes  that
surrounded what were presumed to be unlabeled neuronal
profiles.
LGN layers receiving input from the intact optic nerve
and the ocular dominance bands in V1 associated with the
normal eye were significantly less immunoreactive for GFAP.
At high power, GFAP immunoreactivity in the normal eye
layers/bands demonstrated sparse labeling of thin, astrocytic
processes and few somatic profiles (Figure 1G and Figure
2G).
Microglial activation was assessed by immunoreactivity
to MAC-1. MAC-1, also known as CD 11b, is a component
of the complement receptor C3b. All ONT brains processed
for MAC-1 immunoreactivity demonstrated robust labeling in
the treated layers/bands in the LGN (n=2) and V1 (n=3; Figure
1C,H, Figure 2C,H, and Figure 5B,C). Both the cytoplasm and
processes  of  microglial  cells  displayed  robust
immunoreactivity.  The  diameter  of  the  immunoreactive
profiles in the LGN and V1 were 10.5 µm (±0.4 SD) and
9.5 µm (±0.4 SD), respectively. In the normal eye layers/
bands of the LGN and V1, few immunoreactive cell bodies or
processes were present (Figure 1I and Figure 2I,).
We performed a paired t-test to verify that, based on cell
diameter, the population of GFAP cells was distinct from the
population of MAC-1 immunoreactive cells in the LGN of
ONT brains (p<0.05). This test also confirmed that GFAP and
MAC-1 positive cells were from separate populations in V1
of ONT brains (p<0.05; Figure 6A).
Animals with unilateral ocular hypertension: Vision loss by
unilateral OHT caused a downregulation of CO activity in the
Figure 1. Photomicrographs of serial coronal sections of LGN from an ONT brain. A: Section stained for CO histochemistry demonstrates
reduced CO activity in contralateral (Layers 1,4,6) eye layers. B: Serial section stained for GFAP immunohistochemistry demonstrates denser
reaction product in the contralateral eye layers. C: Serial sections stained for MAC-1 immunohistochemistry demonstrates a denser staining
pattern in the contralateral eye layers. Arrows point to high power photographs (100X) of treated versus normal LGN layers stained for CO
(D, E), GFAP (F, G), or MAC-1 (H, I). Note astrocytic profiles and processes in F and microglial profiles in H.
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2221LGN  layers  innervated  by  the  OHT  eye  in  all  six  brains
processed. Each animal experienced different degrees of IOP
elevation, ranging from 35 to 51 mmHg. Furthermore, the
durations of elevated IOP also differed among the animals,
ranging from 14 to 58 days. The calculated integral values,
which reflect the relative severity of OHT, ranged from 672
to 2,632 (Table 1). The fluctuations in CO density between
the treated and normal eye layers of the LGN were of similar
relative contrast among all six brains. The example shown in
Figure  3A  is  from  an  animal  in  whom  the  ipsilateral
hemisphere was processed, and thus the downregulation in
CO activity was evident in layers 2 (magnocellular) and layers
3, 5 (parvocellular) of the LGN (Figure 3D,E). The example
shown  in  Figure  5A  is  from  an  animal  in  whom  the
contralateral  hemisphere  was  processed,  and  thus  the
downregulation in CO activity was evident in layers 1, 4, and
6.  CO  histochemistry  of  tangential  sections  through  V1
revealed  a  series  of  lightly  and  darkly  stained  ocular
dominance  bands  in  layer  4C  (Figure  4A),  reflecting  a
transsynaptic  reduction  in  activity  of  the  geniculocortical
afferent pathway associated with the OHT eye. The observed
pattern of CO staining in the LGN and V1 was consistent with
the results after vision loss by ONT as described above and
consistent with earlier studies after short-term and long-term
unilateral OHT [21-23].
Astrocyte activation after unilateral OHT was assessed
with GFAP immunoreactivity. All OHT brains processed for
GFAP  immunoreactivity  demonstrated  robust
immunostaining in the treated eye layers of the LGN (n=3),
and moderate to robust immunostaining in the treated ocular
dominance bands of V1 (n=5; Figure 3B, Figure 4B, and
Figure  5A).  Higher  power  images  of  GFAP
immunohistochemistry demonstrated labeling of astrocytic
processes  often  surrounding  what  were  presumed  to  be
unlabeled neuronal profiles (Figure 3F and Figure 4F). The
mean diameter of the GFAP immunoreactive cell bodies in
the parvocellular layers of the LGN was 14.0 µm (±0.3 SD),
while  the  mean  diameter  of  the  GFAP  immunoreactive
profiles in V1 was 11.1 µm (±1.1 SD). The normal eye layers/
bands in the LGN and V1 displayed background levels of
immunoreactivity for GFAP; this was evident particularly at
low power (Figure 3B, Figure 4B, and Figure 5A). At high
power, GFAP immunoreactivity in the normal eye layers and
ocular dominance bands displayed occasional thin, astrocytic
Figure 2. Photomicrographs of serial tangential sections through layer 4C of V1 from an ONT brain. A: Section stained for CO histochemistry
demonstrates ocular dominance bands in tangential sections through layer 4c of V1. Note the treated eye bands (d) demonstrate lighter, less
dense CO staining. B: A serial section stained for GFAP immunohistochemistry demonstrates denser, more robust immunoreactivity in the
ocular dominance bands associated with the treated eye (d). C: A serial section stained for MAC-1 immunohistochemistry demonstrates more
robust immunoreactivity in the ocular dominance bands associated with the treated eye (d). Arrows point to high power photographs (100X)
are shown and contrast staining in treated and normal eye bands for CO (D, E), GFAP (F, G), or MAC-1 (H, I) immunoreactivity. Note
astrocytic profiles and processes in F and microglial profiles in H.
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2222processes  that  were  labeled,  but  these  processes  rarely
outlined presumably unlabeled neuronal profiles (Figure 3G
and  Figure  4G).  We  performed  a  two-sample  t-test  to
determine,  based  on  cell  diameter,  whether  the  GFAP
immunoreactive cells in the OHT and the ONT brains were
from the same population. The tests demonstrated that, based
on cell diameter, GFAP immunoreactive cells in the LGN of
the ONT and OHT brains were from the same population
(p=0.595).  This  was  also  confirmed  for  the  GFAP
immunoreactive cells in V1 of the ONT and OHT (p=0.476;
Figure 6B).
MAC-1 immunoreactivity was at background levels in
the LGN (Figure 3C and Figure 5A) and V1 (Figure 4C) of
the animals with unilateral OHT. There were no fluctuations
in immunoreactivity between treated and normal eye layers of
the LGN or in the ocular dominance bands in V1; there was a
uniform staining throughout the LGN and V1 of all animals
tested (n=3; Figure 3H,I and Figure 4H,I).
DISCUSSION
Glaucomatous  loss  of  retinal  ganglion  cells  can  cause
neurodegeneration in the central visual pathways in animal
models [15-20] and in humans [26,27,56]. An understanding
of the early events associated with neurodegeneration that
may take place in the CNS after elevated IOP would be useful
in developing strategies to prevent atrophy of central neurons
in the LGN and V1. Our study is significant in that it is one
of the first to examine early metabolic activity loss and glial
response in the CNS within the initial 60 days after unilateral
elevated IOP in a primate model of OHT. Effects of elevated
IOP on retinal ganglion cells in this primate model are usually
slow  and  progressive,  and  thus  mimic  the  human  disease
better than other, more severe models that result in retinal
ganglion cell death over shorter time frames. For comparison,
we also studied the metabolic activity and the glial responses
after unilateral ONT. ONT results in neuronal cell loss by
transsynaptic (anterograde) degeneration in the CNS.
Our findings revealed a substantial drop in metabolic
activity, as assessed with CO histochemistry, in the treated
eye bands of the LGN and V1 at all time points studied for
both OHT and ONT. Loss of CO activity in the CNS after
monocular  vision  loss  in  the  adult  primate  has  been
documented  as  early  as  14  h  after  an  intraocular  TTX
injection, and thus represents one of the earliest measurable
responses to loss of visual inputs to the retinogeniculocortical
pathway [57]. Measurement of decreased neuronal metabolic
activity  may  therefore  have  value  as  a  surrogate  for
determining functional loss in the CNS [29].
Figure 3. Photomicrographs of coronal sections of LGN from OHT brains. A: Section stained for CO histochemistry demonstrates reduced
CO activity in ipsilateral eye layers (Layers 2, 3, 5). B: Serial section stained for GFAP immunohistochemistry demonstrates denser reaction
product in the contralateral eye layers (Layers 1, 4, 6). C: Section stained for MAC-1 immunohistochemistry demonstrating uniform labeling
throughout all LGN layers. Arrows point to high power photographs (100X) are shown and contrast staining in treated and normal eye bands
for CO (D, E), GFAP (F, G), or MAC-1 (H, I) immunoreactivity. Note astrocytic profiles and processes in F and lack of labeled profiles in H
and I.
Molecular Vision 2009; 15:2217-2229 <http://www.molvis.org/molvis/v15/a239> © 2009 Molecular Vision
2223In this study, we were able to assess a concomitant rise
in GFAP immunoreactivity, a marker of astrocyte activation,
in spatial register with treated eye bands in both ONT and
OHT animals. Astrocytes are known to influence synaptic
activity by forming glutamate precursors [58,59]. Gordon et
al. found that astrocytes can also modulate neuronal activity
indirectly  by  changing  the  blood  flow  and  the  cerebral
vasculature  [33].  Astrocytic  reactivity  after  sensory
deafferentation was shown in the chick cochlear nucleus and
in the rat LGN after blockade of action potentials by TTX
injections and after enucleation [30-32]. However none of the
studies,  thus  far,  have  demonstrated  whether  long-term
astrocytic reactivity can facilitate recovery of synaptic activity
after loss of afferent activity. Further studies are needed to
pinpoint  the  role  of  glial  activation  after  loss  of  sensory
afferents, and to determine, for example, whether astrocytes
have  a  role  in  initiating  neurodegeneration.  Interestingly,
Pekny et al. [60] suggest that reactive astrocytes may play an
important role in neuroprotection in the early stages of injury,
but may also inhibit CNS plasticity at a later stage after injury.
In  addition  to  astrocyte  activation,  we  observed  a
microglial response within 28 days after ONT. The microglial
activation was robust in the ONT, but not OHT, brains, and
predictable given that nerve transections are known to cause
anterograde neurodegeneration. While we did not observe a
microglial response in the CNS after OHT in the primate
model, Wang et al. reported microglial activation in rodents
with elevated IOP [49]. Differences in species as well as the
method of inducing elevated IOP used in Wang et al.’s study
may account for the observed differences in the microglial
activation in the rodent LGN [49]. Microglial activation has
also been reported in the optic nerve head of experimental
glaucoma and implicated in the loss of retinal ganglion cells
in both animal models [61-63] and in human glaucoma [64,
65]. Because of the significant microglial response in the
retina  after  elevated  IOP,  it  was  suggested  that  targeting
microglial  activation  may  be  effective  at  rescuing  retinal
ganglion cells from atrophy [66-68]. Interestingly, however,
in our study there was no measurable microglial response in
the LGN or V1 of the OHT brains even after durations as long
as  58  days  post  elevated  IOP.  As  microglia  respond
principally to injury or neuronal damage and remove neuronal
debris, the lack of their activation in our short elevated IOP
animals suggest cell loss has not occurred yet. Other studies
of longer elevated IOP duration have shown neuronal cell loss
[16,18-22,27,28,46]. The absence of neuronal loss, and other
irreversible events, at two months suggests that it may be
desirable to develop treatments that can be used soon after the
Figure 4. Photomicrographs of serial tangential sections through layer 4C of V1 from an OHT brain. A: Section stained for CO histochemistry
demonstrates ocular dominance bands in tangential sections through layer 4C of V1. Note the treated eye bands (d) demonstrate lighter, less
dense CO staining. B: A serial section stained for GFAP immunohistochemistry demonstrates denser, more robust immunoreactivity in the
ocular dominance bands associated with the treated eye (d). C: A serial section stained for MAC-1 immunohistochemistry demonstrates
uniform immunoreactivity. Arrows point to high power photographs (100X) of the treated and normal ocular dominance bands stained for
CO (D, E), GFAP (F, G), or MAC-1 (H, I). Note astrocytic profiles and processes in F and lack of labeled microglial profiles in H and I.
Molecular Vision 2009; 15:2217-2229 <http://www.molvis.org/molvis/v15/a239> © 2009 Molecular Vision
2224onset  of  glaucoma,  which  will  protect  against  late  stage
neurodegenerative cell loss. It will be important to assess the
microglial and astrocyte response in the LGN and V1 after
unilateral  OHT  lasting  beyond  the  two  months  duration
studied here, to identify the sequence of cellular events that
occur after astrocyte activation and before neuronal cell loss.
Sasaoka et al. [69] reported GFAP immunoreactivity as well
as  neuronal  cell  loss  in  the  LGN  after  11–18  weeks  of
unilateral OHT in two cynomolgus monkeys. While Sasaoka
et al. [69] did not also assess for microglial activation in this
study, they did assess microglia activation in a subsequent
study and concluded that microglial activation is detectable in
positron  emission  tomography  after  unilateral  OHT  in  a
primate  model  [70].  Thus,  assessing  metabolic  activity,
astrocyte reactivity, or microglial activation by noninvasive
imaging of the CNS may be helpful in the early detection of
Figure 5. GFAP and MAC-1 staining in
the LGN and area V1. A: In the LGN of
the ONT brains, GFAP immunoreactive
cells  (black  bars,  14.2±0.4  SD)  are
larger than the MAC-1 immunoreactive
cells (white bars, 10.5±0.4 SD). In V1,
GFAP immunoreactive cells were again
larger (black bar, 11.8±0.9 SD) than the
MAC-1  immunoreactive  cells  (white
bar,  9.5±0.4  SD).  Asterisks  indicate
significance at the p<0.05 level. B: A
comparison  of  the  GFAP
immunoreactive  cells  in  the  LGN  of
ONT (14.2±0.4 SD) and OHT (14.0±0.3
SD)  brains  revealed  that  the  two
populations  were  indistinguishable
based on cell size. A similar comparison
of GFAP immunoreactive cells in V1 of
ONT (11.8±0.9 SD) and OHT (11.1±1.1
SD) revealed no difference in the size
range in GFAP immunoreactive cells in
V1.
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2225central  changes  associated  with  glaucoma  that  cannot  be
assessed at the level of the retina.
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